Follicular Lymphoma (ASH 2022) Basic Listing

Updates in Follicular Lymphoma

From the ASH Annual Meeting & Exposition

Conference Coverage

Analyzing Response Rate and Line of Therapy Correlation Among Patients With R/R Follicular Lymphoma

12/10/2023

Featuring Tycel Phillips, MD

At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Conference Coverage

Epcoritamab Plus Rituximab and Lenalidomide Yields High Complete Metabolic Response Rate in Follicular Lymphoma

12/16/2022

Janelle Bradley

In patients with relapsed or refractory follicular lymphoma, epcoritamab combined with rituximab and lenalidomide demonstrated manageable safety and a high complete metabolic response rate, according to findings from a phase 1/2 study.

In patients with relapsed or...

12/16/2022

Oncology

Conference Coverage

Epcoritamab With Rituximab Plus Lenalidomide Demonstrates Promising Efficacy as First-Line Therapy for Patients With Follicular Lymphoma

12/16/2022

Epcoritamab combined with rituximab plus lenalidomide regimen showed encouraging efficacy as a first-line treatment for follicular lymphoma, according to data presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

Epcoritamab combined with...

12/16/2022

Oncology

Conference Coverage

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine for Treatment of Patients With R/R Follicular Lymphoma

12/16/2022

Usage of regimens of lenalidomide-rituximab or lenalidomide-rituximab-bendamustine were associated with less severe toxicity than expected in patients with R/R FL, according to analysis of a phase 2 trial.

Usage of regimens of...

12/16/2022

Oncology

Conference Coverage

Rituximab Monotherapy Prolongs Time to Next Treatment in Low Tumor Burden Follicular Lymphoma

12/12/2022

Janelle Bradley

Long-term findings from the phase 3 Watch & Wait trial show that after a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients with low tumor burden follicular lymphoma.

Long-term findings from the...

12/12/2022

Oncology

Follicular Lymphoma (ASH 2022) Basic Listing

Specialties

Events

Year Round Education

HMP Global Products